Defining the interactions of senescent immune cells and skeletal cells
定义衰老免疫细胞和骨骼细胞的相互作用
基本信息
- 批准号:10424667
- 负责人:
- 金额:$ 49.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptive TransferAgeAge-Related Bone LossAge-Related OsteoporosisAgingAnimalsApoptosisAutomobile DrivingBiological MarkersBone MarrowCDKN2A geneCell AgingCell modelCellsCharacteristicsChromatinChronic DiseaseChronologyCoculture TechniquesComplementCytometryDNA DamageDNA RepairDefectDegenerative DisorderDeteriorationERCC1 geneEtiologyExtracellular MatrixGeneticGenetic ModelsHumanImmuneImmune systemIn VitroInflammationInflammatoryInterventionLOX geneLaboratoriesLeadLymphoid CellMediatingMediator of activation proteinModelingMusMyeloid CellsOrganOsteocytesOsteoporosisPhenotypePopulationPremature aging syndromeProteinsRegulationRepair ComplexResistanceRoleSkeletonTestingTimeTissuesTransgenic MiceUp-RegulationWorkage relatedagedbonecell agechemokinecytokineexperimental studyfunctional declineimmunosenescencein vivomouse modelneutrophilnew therapeutic targetnovelosteoimmunologyparacrineprematurepreventsenescencesingle-cell RNA sequencingskeletaltelomere
项目摘要
Cellular senescence is now recognized as one of the fundamental aging mechanisms contributing to multiple
age-related degenerative conditions, including osteoporosis. In previous studies, we have systematically
identified senescent cells in the bone microenvironment and demonstrated a causal role for senescent cells in
mediating age-related bone loss in mice. In recent studies, we used a novel transgenic mouse model, p16-
LOX-ATTAC, capable of temporal- and cell-specific senescent cell clearance, and found that in contrast to
global clearance of senescent cells using the (p16)-INK-ATTAC model, clearance specifically of senescent
osteocytes only partially replicated the beneficial skeletal effects of global senescent cell clearance, suggesting
an important role for other cells in the bone microenvironment (e.g., immune cells) in contributing to skeletal
aging. In addition, in our previous work, we demonstrated a dramatic upregulation of the senescence-
associated secretory phenotype (SASP) in bone marrow myeloid cells with aging, and more recent studies by
our investigative team have shown that with aging, activated neutrophils can induce senescence in multiple
tissues in a paracrine manner. Conversely, senescent cells are capable of attracting neutrophils, which then
further propagate senescence to other cells. Collectively, these studies point to previously unexplored cross-
talk between skeletal and immune cells, specifically in the context of cellular senescence. Thus, our central
hypothesis is that senescence of immune cells contributes to skeletal deterioration and conversely, senescent
skeletal cells attract and contribute to an inflammatory and/or senescent phenotype of immune cells. We will
test this hypothesis by examining the effects of senescent immune cells on bone and in the reverse
experiment, evaluating the effects of senescent skeletal cells on immune cells. Our proposed studies make use
of novel mouse models: p16-LOX-ATTAC mice, developed in the Khosla/Monroe laboratory, which are capable
of temporal- and cell-specific (when crossed with a Cre mouse) senescent cell clearance; and Ercc1-/fl mice,
developed by Drs. Niedernhofer and Robbins (Co-Is), where we can induce a tissue-specific DNA repair defect
leading to premature cellular senescence only in that tissue (e.g., immune or skeletal cells). Collectively, our
studies will address a number of fundamental questions relevant to osteoimmunology: (1) What are the specific
populations of bone marrow immune cells that undergo senescence with aging using strictly defined criteria for
cellular senescence (rather than the much broader umbrella of “immunosenescence” that includes
inflammatory, but not necessarily senescent cells); (2) Does chronological or premature aging of the immune
system cause skeletal deterioration?; (3) Conversely, do senescent skeletal cells lead to senescence, or at
least inflammation, in bone marrow immune cells and does this further propagate senescence to other skeletal
cells and perhaps systemically?; and (4) What are the potential mediators of the cross-talk between senescent
skeletal cells and senescent/inflammatory immune cells?
细胞衰老现在被认为是导致多种衰老的基本衰老机制之一。
与年龄相关的退行性疾病,包括骨质疏松症。在以前的研究中,我们系统地
鉴定了骨微环境中的衰老细胞,并证明了衰老细胞在骨微环境中的因果作用。
介导小鼠年龄相关的骨质流失。在最近的研究中,我们使用了一种新的转基因小鼠模型,p16-
LOX-ATTAC,能够时间特异性和细胞特异性的衰老细胞清除,并发现与
使用(p16)-INK-ATTAC模型的衰老细胞的整体清除,衰老细胞的特异性清除
骨细胞仅部分复制了整体衰老细胞清除的有益骨骼效应,表明
其它细胞在骨微环境中的重要作用(例如,免疫细胞)在促进骨骼
衰老此外,在我们之前的工作中,我们证明了衰老的戏剧性上调-
相关的分泌表型(SASP)在骨髓髓样细胞与衰老,以及最近的研究,
我们的研究小组已经表明,随着年龄的增长,激活的中性粒细胞可以诱导多种细胞的衰老,
以旁分泌的方式。相反,衰老细胞能够吸引中性粒细胞,
进一步将衰老传播到其他细胞。总的来说,这些研究指出了以前未探索的交叉-
骨骼和免疫细胞之间的对话,特别是在细胞衰老的背景下。因此,我们的中央
一种假说认为,免疫细胞的衰老导致骨骼退化,相反,
骨骼细胞吸引并促成免疫细胞的炎性和/或衰老表型。我们将
通过检测衰老免疫细胞对骨骼的影响来验证这一假设,
实验,评估衰老骨骼细胞对免疫细胞的影响。我们提出的研究利用
新型小鼠模型:p16-LOX-ATTAC小鼠,在Khosla/门罗实验室开发,
时间特异性和细胞特异性(当与Cre小鼠杂交时)衰老细胞清除;和Ercc 1-/fl小鼠,
由Niedernhofer和Robbins博士(Co-Is)开发,我们可以诱导组织特异性DNA修复缺陷
导致仅在该组织中过早的细胞衰老(例如,免疫或骨骼细胞)。总体而言,我们
研究将解决一些与骨免疫学相关的基本问题:(1)具体是什么?
使用严格定义的标准,
细胞衰老(而不是更广泛的“免疫衰老”,包括
炎性细胞,但不一定是衰老细胞);(2)免疫系统的时间性或过早老化是否
系统导致骨骼退化?(3)相反,衰老的骨骼细胞会导致衰老,还是
最少的炎症,在骨髓免疫细胞,这是否进一步传播衰老到其他骨骼
细胞,也许是系统性的?以及(4)衰老细胞与衰老细胞之间的相互作用的潜在介质是什么?
骨骼细胞和衰老/炎症免疫细胞?
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sundeep Khosla其他文献
Sundeep Khosla的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sundeep Khosla', 18)}}的其他基金
Defining the interactions of senescent immune cells and skeletal cells
定义衰老免疫细胞和骨骼细胞的相互作用
- 批准号:
10629252 - 财政年份:2022
- 资助金额:
$ 49.05万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 49.05万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 49.05万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 49.05万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 49.05万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 49.05万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 49.05万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 49.05万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 49.05万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 49.05万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 49.05万 - 项目类别: